瘢痕修复激光治疗的保险覆盖碎片化现状
该研究横断面分析了美国60家最大健康保险公司对瘢痕修复激光治疗的保险政策,并回顾性收集本机构2017至2022年理赔数据。60家中仅11家(18.3%)有瘢痕修复专项政策,19家认为存在难治性功能障碍时激光治疗为医学必要,3家任何情况下均拒保。本机构1531例烧伤瘢痕激光治疗理赔中13.8%被拒,Medicare和Medicaid参保者获赔几率显著高于商业保险者,研究期间获赔几率每年下降14.5%。
要点
- 60家美国最大健康保险公司中仅11家(18.3%)制定了瘢痕修复激光治疗专项政策。
- 本机构1531例烧伤瘢痕激光治疗理赔中13.8%被拒。
- Medicare(ORadj 3.78)和Medicaid(ORadj 2.80)参保者获赔几率显著高于商业保险者(P < .01)。
核心结论
- 激光治疗是有效手段,但创伤性瘢痕患者获取该治疗的机会并不广泛;本机构数据提示自2017年以来保险覆盖下降趋势可能进一步削弱可及性,需要策略保护患者获得这一改变生活的治疗。
研究设计与样本
- 横断面分析美国按参保人数和市场份额排名前60的健康保险公司,识别其瘢痕修复激光治疗政策并提取文件记录、预授权与持续授权要求及治疗指南。
- 回顾性收集本机构2017年至2022年理赔数据以调查报销趋势。
主要发现
- 60家最大健康保险公司中,11家(18.3%)有瘢痕修复政策,40家(66.7%)有包含瘢痕修复的重建手术政策。
- 19家政策认为在先治疗难治性功能障碍证据下激光治疗为医学必要,3家在任何情况下均拒绝激光覆盖。
- 本机构提交的1531例烧伤瘢痕激光治疗理赔中13.8%被拒。
- Medicare参保者(ORadj 3.78)和Medicaid参保者(ORadj 2.80)获赔几率显著高于商业保险参保者(P < .01)。
- 研究期间获赔几率每年下降14.5%(ORadj 0.86,P < .01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fractional laser therapy improves skin texture, range of motion, and quality of life for patients with traumatic scars. Nevertheless, anecdotal evidence suggests declining insurance coverage for laser therapy. We aimed to characterize the landscape of insurance coverage for fractional laser therapy present our 6 year reimbursement trends. We cross-sectionally analyzed the 60 largest American health insurers by enrollee size and market share. For each, we identified their laser therapy policy for scar revision and extracted their documentation, prior and continuing authorization requirements and treatment guidelines. We also collected retrospective institutional claims data from 2017 to 2022 to investigate trends in reimbursement. Of the 60 largest health insurers, we identified 11 (18.3%) policies on scar revision and 40 policies (66.7%) on reconstructive surgery, including scar revision. Nineteen policies considered laser therapy medically necessary with evidence of functional impairment refractory to prior treatment. Three insurers denied laser coverage under any circumstance. Of the 1,531 claims submitted by our institution for burn scar laser therapy, 13.8% were denied. Patients with Medicare (ORadj, 3.78) or Medicaid (ORadj, 2.80) had significantly greater odds of coverage than privately insured patients (P < .01). There was a 14.5% annual reduction in the odds of reimbursement during the study period (ORadj, 0.86, P < .01). Laser therapy is a powerful treatment that is not widely available to patients with traumatic scars. Our institutional data suggest this access may be further eclipsed by decreasing trends in coverage since 2017. Strategies are needed to protect patient access to this life-changing treatment.
引用
- Heron MJ, Reinoso TR, Dane JM, et al. The Fractured Insurance Landscape of Laser Therapy for Scar Revision. J Burn Care Res. 2025. PMID: 39269322. doi:10.1093/jbcr/irae173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。